已收录 268921 条政策
 政策提纲
  • 暂无提纲
Acute adverse drug reactions following cardiac catheterization:evidence-based guidance for providers and systems
[摘要] Cardiovascular disease represents a leading source of health loss globally, with an estimated 422 million cases and18 million deaths attributed to cardiovascular disease in 2015 (1). Diagnostic and therapeutic coronary catheterization (CC) are critical interventions for many of these patients, and over 1 million catheterizations are performed in the United States alone each year (2). CC can generally be performed with low peri-procedural risk. For diagnostic procedures, risk of mortality is less than 0.1% and, when combined with percutaneous coronary intervention, between 0.5% and 2% (3,4). Nevertheless, as with any invasive procedure, there are complications of varying severity associated with CC including contrast-induced nephropathy, cholesterol embolization, local vascular injury, hematoma, pseudoaneurysm, conduction disturbance, stroke and myocardial infarction (5).
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 呼吸医学
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文